Hanall Biopharma Cash Flow-to-Debt Ratio
Hanall Biopharma cash flow-to-debt ratio. Hanall Biopharma (009420) has a Cash Flow-to-Debt Ratio of 0.17x as of September 2025, meaning its operating cash flow of ₩7.34 Billion could theoretically repay 0% of its total liabilities (₩44.17 Billion) in one year. Check 009420 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Hanall Biopharma (2011–2024)
Cash flow-to-debt ratio of Hanall Biopharma from 2011 to 2024. Historical debt coverage capacity for Hanall Biopharma across 14 annual periods. Check Hanall Biopharma cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Hanall Biopharma Cash Flow-to-Debt Ratio by Year (2011–2024)
Hanall Biopharma cash flow-to-debt ratio by year from 2011 to 2024. Year-by-year debt coverage analysis for Hanall Biopharma. For the full cash flow conversion analysis, see 009420 cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.21x | ₩9.36 Billion | ₩44.53 Billion | ▼ -62.0% |
| 2023 | 0.55x | ₩29.64 Billion | ₩53.53 Billion | ▼ -0.7% |
| 2022 | 0.56x | ₩25.20 Billion | ₩45.19 Billion | ▲ +2223.1% |
| 2021 | 0.02x | ₩839.87 Million | ₩34.99 Billion | ▲ +0.4% |
| 2020 | 0.02x | ₩929.29 Million | ₩38.86 Billion | ▼ -94.1% |
| 2019 | 0.40x | ₩20.49 Billion | ₩50.97 Billion | ▲ +709.4% |
| 2018 | -0.07x | ₩-2.99 Billion | ₩45.39 Billion | ▼ -109.0% |
| 2017 | 0.73x | ₩42.14 Billion | ₩57.50 Billion | ▲ +278.0% |
| 2016 | 0.19x | ₩3.95 Billion | ₩20.37 Billion | ▲ +1035.7% |
| 2015 | -0.02x | ₩-454.02 Million | ₩21.91 Billion | ▲ +75.6% |
| 2014 | -0.09x | ₩-3.52 Billion | ₩41.36 Billion | ▲ +58.2% |
| 2013 | -0.20x | ₩-7.78 Billion | ₩38.23 Billion | ▼ -522.4% |
| 2012 | 0.05x | ₩2.20 Billion | ₩45.60 Billion | ▼ -64.4% |
| 2011 | 0.14x | ₩7.41 Billion | ₩54.75 Billion | — |